Last reviewed · How we verify
Sequential therapy 10 days — Competitive Intelligence Brief
marketed
Antibiotic
Infectious Diseases
Small molecule
Live · refreshed every 30 min
Target snapshot
Sequential therapy 10 days (Sequential therapy 10 days) — Incheon St.Mary's Hospital. Sequential therapy is a treatment approach that involves a combination of antibiotics to treat bacterial infections.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sequential therapy 10 days TARGET | Sequential therapy 10 days | Incheon St.Mary's Hospital | marketed | Antibiotic | ||
| Avelox | moxifloxacin | Bayer AG | marketed | Fluoroquinolone antibiotic (fourth-generation) | DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A | 1999-12-10 |
| Zithromax | azithromycin | Pfizer Inc. | marketed | Macrolide antibiotic (azalide) | Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor | 1991-11-01 |
| Cipro | ciprofloxacin | Bayer AG | marketed | Fluoroquinolone antibiotic | DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A | 1987-10-22 |
| Rocephin | ceftriaxone | Generic (originally Roche) | marketed | Cephalosporin antibiotic (third-generation) | Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A | 1984-12-21 |
| Amoxil | amoxicillin | Generic (originally Beecham/GSK) | marketed | Aminopenicillin (Beta-lactam antibiotic) | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C | 1972-01-01 |
| Cleocin | clindamycin | Generic (originally Upjohn/Pfizer) | marketed | Lincosamide antibiotic | 50S ribosomal protein L10 | 1970-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Amoxil · 8778924 · Compound · US
- — Amoxil · 8357394 · Formulation · US
- — Amoxil · 8299052 · Method of Use · US
- — Cipro · 9205048 · Method of Use · US
- — Cipro · 9603796 · Compound · US
- — Cipro · 11369566 · Formulation · US
- — Cipro · 9233068 · Formulation · US
- — Cipro · 8318817 · Method of Use · US
- — Cipro · 9220796 · Formulation · US
- — Cipro · 11040004 · Method of Use · US
- — Cipro · 11246863 · Formulation · US
Sponsor landscape (Antibiotic class)
- Bausch Health Americas, Inc. · 2 drugs in this class
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- BioVersys AG · 1 drug in this class
- Bosnalijek D.D · 1 drug in this class
- Capital Medical University · 1 drug in this class
- Dr. Reddy's Laboratories Limited · 1 drug in this class
- Incheon St.Mary's Hospital · 1 drug in this class
- Jomaa Pharma GmbH · 1 drug in this class
- King Abdulaziz University · 1 drug in this class
- Menzies School of Health Research · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sequential therapy 10 days CI watch — RSS
- Sequential therapy 10 days CI watch — Atom
- Sequential therapy 10 days CI watch — JSON
- Sequential therapy 10 days alone — RSS
- Whole Antibiotic class — RSS
Cite this brief
Drug Landscape (2026). Sequential therapy 10 days — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-therapy-10-days. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab